Skip to content

Injection of crosslinked sodium hyaluronate gel Belotero Balance Lidocaine for correction of nasolabial folds in Chinese subjects

A prospective, subject- and evaluator blind, randomized, multi-center, controlled clinical investigation to prove the non-inferiority of Belotero Balance Lidocaine versus Restylane after single injection for correction of moderate nasolabial folds (NLFs) over 1 year in Chinese subjects

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058113
Enrollment
Unknown
Registered
2022-03-30
Start date
2017-11-27
Completion date
Unknown
Last updated
2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasolabial folds

Interventions

Two groups:dermal filler injection

Sponsors

Beijing Anzhen Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. No less than 18 years; 2. At the time of screening, the independent blind evaluator evaluated the symmetrical nasolabial fold wrinkles as moderate (score 3) according to WSRS (the ratings on both sides of the face are the same); 3. Hope to correct bilateral nasolabial wrinkles; 4. Women with the possibility of pregnancy must take effective contraceptive measures. The serum pregnancy test must be negative when screening, and the urine pregnancy test must be negative at baseline.

Exclusion criteria

Exclusion criteria: 1. The subject has undergone surgery or permanent implantation or left scars at the site to be treated; 2. The site to be treated has received silicone, polymethylmethacrylate, fat injection, poly L-lactic acid or permanent subcutaneous filler; 3. The area to be treated has been treated with hyaluronic acid (HA) filler in the past 12 months; 4. In the past six months, the face has received or plans to receive skin treatment during the study (such as toxin treatment, facial laser cauterization or dot matrix laser, microcrystalline skin replacement, chemical skin replacement; 5. non-invasive skin tightening, hair removal and surgical treatment); 6. It is known that it is allergic to a certain component of the test medical device, such as sodium hyaluronate, lidocaine or amide anesthetics, or any other component of the device; 7. Have a history of hyperpigmentation or hypopigmentation, scar formation, or hypertrophic scar; 8. There is acute inflammation or infection (such as acne, rash, cyst, etc.) at the injection site, or chronic or recurrent infection (such as herpes) or inflammation history that may interfere with the research results or increase the risk of adverse events.

Design outcomes

Primary

MeasureTime frame
Wrinkle Severity Rating Scale (WSRS);

Countries

China

Contacts

Public ContactWenzhi Li

Beijing Anzhen Hospital

liwenzhizx@163.com+86 18911662950

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026